Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Birch Pollen Allergy Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Birch Pollen Allergy Overview | 7 | 1 |
| Birch Pollen Allergy Therapeutics under Development by Companies | 8 | 1 |
| Birch Pollen Allergy Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Birch Pollen Allergy Products under Development by Companies | 12 | 1 |
| Birch Pollen Allergy Companies Involved in Therapeutics Development | 13 | 7 |
| ALK-Abello A/S | 13 | 1 |
| Allergopharma GmbH &Co. KG | 14 | 1 |
| Anergis SA | 15 | 1 |
| Biomay AG | 16 | 1 |
| Circassia Pharmaceuticals Plc | 17 | 1 |
| HAL Allergy BV | 18 | 1 |
| Stallergenes SAS | 19 | 1 |
| Birch Pollen Allergy Therapeutics Assessment | 20 | 6 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 1 |
| Assessment by Route of Administration | 22 | 2 |
| Assessment by Molecule Type | 24 | 2 |
| Drug Profiles | 26 | 11 |
| Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis Drug Profile | 26 | 1 |
| Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis Drug Profile | 27 | 1 |
| AllerT Drug Profile | 28 | 4 |
| Birch Pollen Allergoid Drug Profile | 32 | 1 |
| BM-31 Drug Profile | 33 | 1 |
| PL-102 Drug Profile | 34 | 1 |
| STG-210 Drug Profile | 35 | 1 |
| Vaccine for Birch Pollen Allergy Drug Profile | 36 | 1 |
| Birch Pollen Allergy Dormant Projects | 37 | 1 |
| Birch Pollen Allergy Discontinued Products | 38 | 1 |
| Birch Pollen Allergy Product Development Milestones | 39 | 9 |
| Featured News &Press Releases | 39 | 1 |
| Jun 07, 2016: Anergis to Present New Data on Lead Compound AllerT at the 35th European Academy of Allergy and Clinical Immunology Congress 2016 | 39 | 1 |
| Apr 01, 2015: Anergis Announces Completion of Treatment in AllerT Phase II Dose-Ranging Trial | 40 | 1 |
| Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen | 40 | 1 |
| Feb 23, 2015: Anergis Presents Sustained Efficacy Data from its AllerT Phase IIb Trial at the AAAAI Annual Meeting | 41 | 1 |
| Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT | 41 | 1 |
| Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT | 42 | 1 |
| May 27, 2014: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen | 42 | 1 |
| Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT | 43 | 1 |
| Feb 27, 2014: Phase IIb Results of Anergis Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego | 43 | 1 |
| Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT | 44 | 1 |
| Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT | 44 | 1 |
| Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT | 45 | 1 |
| Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment | 45 | 1 |
| Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen | 46 | 1 |
| Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US | 46 | 2 |
| Appendix | 48 | 2 |
| Methodology | 48 | 1 |
| Coverage | 48 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Expert Panel Validation | 48 | 1 |
| Contact Us | 48 | 1 |
| Disclaimer | 49 | 1 |